PFE Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Stats
Today's Volume	18.67M
Average Volume	42.58M
Market Cap	148.34B
EPS	$0 ( 2024-01-30 )
Next earnings date	( $0.560 ) 2024-05-01
Last Dividend	$0.410 ( 2023-11-09 )
Next Dividend	$0 ( N/A )
P/E	71.00
ATR14	$0.0160 (0.06%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-15	Damico Jennifer B.	Buy	54	Phantom Stock Units SSP
2024-04-15	Bourla Albert	Buy	20	Phantom Stock Units SSP
2024-04-10	Damico Jennifer B.	Buy	108	Phantom Stock Units SSP
2024-04-10	Bourla Albert	Buy	18	Phantom Stock Units SSP
2024-03-28	Damico Jennifer B.	Buy	49	Phantom Stock Units SSP

INSIDER POWER
70.26
Last 100 transactions
Buy: 4 247 041 \| Sell: 745 543

Volume Correlation

Long: -0.13 (neutral)

Short: -0.01 (neutral)

Signal:(48.671) Neutral

Pfizer Inc Correlation

10 Most Positive Correlations
PCQ	0.969
ZME	0.962
CHGG	0.951
RSF	0.947
GDMA	0.946
TPL	0.941
CALX	0.939
EVTL	0.937
PCK	0.936
K	0.93

10 Most Negative Correlations
WWW	-0.954
HCI	-0.953
NGL-PB	-0.95
FSNB	-0.949
LOCC	-0.949
LHC	-0.948
VNT	-0.947
CRH	-0.945
FTAI	-0.942
JMP	-0.94

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Pfizer Inc Correlation - Currency/Commodity

-0.07
( neutral )

-0.02
( neutral )

0.00
( neutral )

-0.44
( neutral )

-0.05
( neutral )

Pfizer Inc Financials

Annual	2023
Revenue:	$58.50B
Gross Profit:	$29.28B (50.06 %)
EPS:	$0.380

Q4	2023
Revenue:	$14.25B
Gross Profit:	$5.66B (39.70 %)
EPS:	$-0.590

Q3	2023
Revenue:	$13.23B
Gross Profit:	$2.63B (19.87 %)
EPS:	$-0.420

Q3	2023
Revenue:	$13.23B
Gross Profit:	$3.96B (29.95 %)
EPS:	$-0.420

Financial Reports:

No articles found.

Pfizer Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.400 (N/A)	$0.400 (N/A)	$0.410 (N/A)	$0.410 (N/A)	$0.410 (N/A)	$0.410 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Pfizer Inc Dividend Information - Dividend Knight

Dividend Sustainability Score: 6.10 - average (70.40%) | Divividend Growth Potential Score: 4.04 - Stable (19.10%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.00316	1972-08-29
Last Dividend	$0.410	2023-11-09
Next Dividend	$0	N/A
Payout Date	2023-12-04
Next Payout Date	N/A
# dividends	206	--
Total Paid Out	$26.05	--
Avg. Dividend % Per Year	2.24%	--
Score	4.92	--
Div. Sustainability Score	6.10
Div.Growth Potential Score	4.04
Div. Directional Score	5.07	--

Next Divdend (Est)
(2024-07-01)

$0.413 Estimate 39.90 %

Dividend Stability

0.80 Good

Dividend Score

4.92

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
1972	$0.00731	0.90%
1973	$0.0138	1.60%
1974	$0.0156	1.83%
1975	$0.0160	2.52%
1976	$0.0170	3.03%
1977	$0.0196	3.44%
1978	$0.0231	4.27%
1979	$0.0261	3.98%
1980	$0.0285	3.84%
1981	$0.0316	3.01%
1982	$0.0364	3.50%
1983	$0.0460	3.43%
1984	$0.0524	3.66%
1985	$0.0584	3.65%
1986	$0.0648	3.27%
1987	$0.0712	2.91%
1988	$0.0792	4.13%
1989	$0.0868	3.81%
1990	$0.0948	3.37%
1991	$0.104	3.29%
1992	$0.117	1.77%
1993	$0.133	2.32%
1994	$0.149	2.77%
1995	$0.164	2.74%
1996	$0.190	1.93%
1997	$0.215	1.66%
1998	$0.240	1.00%
1999	$0.291	0.75%
2000	$0.342	1.13%
2001	$0.416	0.95%
2002	$0.492	1.30%
2003	$0.568	1.90%
2004	$0.644	1.91%
2005	$0.720	2.87%
2006	$0.912	4.04%
2007	$1.100	4.41%
2008	$1.216	5.59%
2009	$0.760	4.39%
2010	$0.684	3.81%
2011	$0.760	4.53%
2012	$0.836	4.01%
2013	$0.912	3.71%
2014	$0.988	3.42%
2015	$1.064	3.58%
2016	$1.140	3.76%
2017	$1.216	3.88%
2018	$1.292	3.74%
2019	$1.368	3.33%
2020	$1.444	3.89%
2021	$1.560	4.24%
2022	$1.600	2.82%
2023	$1.640	3.20%
2024	$0	0.00%

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
VGI	Dividend Royal	2024-02-09	Monthly	13	7.36%	8.50
JQC	Dividend Royal	2023-11-14	Monthly	22	6.56%	8.50
PHK	Dividend Royal	2023-11-10	Monthly	22	6.88%	8.50
PCF	Dividend King	2023-12-18	Monthly	38	7.05%	8.50
PVL	Dividend King	2023-11-15	Monthly	14	9.37%	8.50
NCV	Dividend Royal	2024-02-09	Monthly	22	7.68%	8.50
MTR	Dividend Diamond	2023-10-30	Monthly	39	10.10%	8.50
SBR	Dividend Royal	2023-11-14	Monthly	38	7.74%	8.50
PDI	Dividend Royal	2023-11-10	Monthly	13	7.86%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0364	1.500	9.27	10.00	[0 - 0.5]
returnOnAssetsTTM	0.00941	1.200	9.69	10.00	[0 - 0.3]
returnOnEquityTTM	0.0221	1.500	-0.866	-1.298	[0.1 - 1]
payoutRatioTTM	4.34	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	0.907	0.800	-0.467	-0.373	[1 - 3]
quickRatioTTM	0.499	0.800	-1.768	-1.415	[0.8 - 2.5]
cashRatioTTM	0.0597	1.500	-0.779	-1.169	[0.2 - 2]
debtRatioTTM	0.320	-1.500	4.67	-7.01	[0 - 0.6]
interestCoverageTTM	1.631	1.000	-0.507	-0.507	[3 - 30]
operatingCashFlowPerShareTTM	1.541	2.00	9.49	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.849	2.00	9.58	10.00	[0 - 20]
debtEquityRatioTTM	0.814	-1.500	6.75	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.490	1.000	5.17	5.17	[0.2 - 0.8]
operatingProfitMarginTTM	0.0616	1.000	-0.768	-0.768	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.120	1.000	-0.444	-0.444	[0.2 - 2]
assetTurnoverTTM	0.258	0.800	-1.612	-1.289	[0.5 - 2]
Total Score				6.10

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	69.71	1.000	3.06	0	[1 - 100]
returnOnEquityTTM	0.0221	2.50	-0.556	-1.298	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.849	2.00	9.72	10.00	[0 - 30]
dividendYielPercentageTTM	6.27	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	1.541	2.00	9.49	10.00	[0 - 30]
payoutRatioTTM	4.34	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	-1.490	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.149	1.000	8.78	0	[0.1 - 0.5]
Total Score				4.04

Pfizer Inc

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.